Organization
Washington University in Saint Louis
4 abstracts
Abstract
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,
Abstract
Germline alterations in patients with lung cancer.Org: Tempus Labs, Inc., Washington University School of Medicine, Washington University in Saint Louis,
Abstract
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.Org: Mary Crowley Cancer Research Center, Washington University in Saint Louis, Brown Cancer Center, Sanford Cancer Center, Prisma Health Cancer Institute,
Abstract
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,